BIDMC 2011 Surgery Research 090612 NP Edits.Indd

Total Page:16

File Type:pdf, Size:1020Kb

BIDMC 2011 Surgery Research 090612 NP Edits.Indd Annual Report January–December 2011 From the Chairman This issue of our Annual Research Report celebrates the tradition of clinical innovation carried on by the Department of Surgery at Beth Israel Deaconess Medical Center since its inception with the Harvard Fifth Surgical Service more than 150 years ago. Opportunities for innovation lie at the interfaces of disciplines — where individuals with diverse viewpoints communicate, examine problems through prisms that reflect very different perspectives, and share distinct ideas from highly disparate fields. This is what germinates new solutions to what were previously perceived as intractable clinical problems. The broad scope of the clinical and fundamental investigations summarized in this report highlight the qualities that are at the core of our department — our desire to nurture intellectual diversity, embrace individual freedom, encourage flexibility, and promote spontaneity and originality. We foster and celebrate these qualities because imaginative and inventive surgeons and investigators, students, residents, and fellows who are given the Elliot L. Chaikof, MD, PhD opportunity to work in diverse collaborations and teams have always been Johnson and Johnson central to the creation of new pathways leading to therapeutic breakthroughs. Professor of Surgery It is the inspiration and ingenuity of our academic community that contribute to the arena of ideas, which has always distinguished surgery at Beth Israel Chairman, Deaconess Medical Center and Harvard medicine. Department of Surgery This report is but a snapshot of the environment and activities within our Surgeon-in-Chief department and its highly interdisciplinary collaborations in the medical, biological, chemical, mathematical, computational, and engineering sciences. As the pace of these scientific and technological advances accelerates, we have many meaningful opportunities to advance the care of our patients in every clinical discipline of surgery. As you will read in this report, our department has a robust research enter- prise with nearly $20 million dollars in funding and 40 NIH grants, as well as some 400 publications generated by our faculty and students. The impres- sive work within our department continues to attract the brightest young women and men, who perform cutting-edge science that crosses boundaries. The individuals whose research is highlighted in this report represent the very best of our department and the medical center. One and all, they are dedicated to fulfilling our mission — of serving our communities, improving health through innovation and discovery, and preparing future leaders in American surgery. “We need to cut passages between shafts we have already dug instead of merely digging the same old shafts deeper and deeper.” Stringfellow Barr (1897–1982), author and educator Department of Surgery Research Annual Report 2011 | i ii | Beth Israel Deaconess Medical Center Overview of Surgical Research ................................................1 Table of Contents Division of Acute Care Surgery .............................................. 35 Carl J. Hauser, MD .................................................................. 37 Wolfgang Junger, PhD .............................................................. 39 Teresa Sanchez, PhD ................................................................. 43 Division of Cardiac Surgery .................................................. 47 Kamal R. Khabbaz, MD Robert C. Hagberg, MD David Liu, MD ........................................................................ 49 Sidney Levitsky, MD James D. McCully, PhD ............................................................. 57 Division of Colon and Rectal Surgery ..................................... 63 Deborah A. Nagle, MD Vitaliy Y. Poylin, MD Jeanne Quinn, NP Kristin Messer, RN ................................................................... 65 Division of General Surgery .................................................. 71 George L. Blackburn, MD, PhD Jin-Rong Zhou, PhD ................................................................ 75 Mark P. Callery, MD, FACS Tara S. Kent, MD Charles M. Vollmer, Jr. MD, FACS ............................................... 89 Rosemary B. Duda, MD, MPH .................................................... 95 Susan J. Hagen, PhD ................................................................ 97 Per-Olof Hasselgren, MD, PhD ................................................... 103 Daniel B. Jones, MD, MS, FACS .................................................. 107 Ranjna Sharma, MD ............................................................... 115 Division of Ophthalmology ................................................ 117 Jorge G. Arroyo, MD, MPH ....................................................... 119 Division of Plastic and Reconstructive Surgery ...................... 121 Department of Surgery Research Annual Report 2011 | iii Table of Contents Division of Podiatry ........................................................... 145 Aristidis Veves, MD, DSc .......................................................... 147 Division of Surgical Oncology ............................................. 153 Jennifer Tseng, MD, MPH ........................................................ 155 Division of Transplantation, Transplant Institute ................... 161 Amy R. Evenson, MD .............................................................. 165 Douglas W. Hanto, MD, PhD ..................................................... 167 Maria Koulmanda, MSc, PhD .................................................... 173 Dieder A. Mandelbrot, MD ....................................................... 177 Leo E. Otterbein, PhD ............................................................. 179 Martha Pavlakis, MD ............................................................... 183 Simon C. Robson, MD, PhD, FRCP ............................................. 185 James R. Rodrigue, PhD ............................................................ 189 Terry B. Strom, MD ................................................................197 Laurence A. Turka, MD ...........................................................201 M. Todd Valerius, PhD ............................................................205 Barbara Wegiel, PhD ...............................................................209 Division of Urology ........................................................... 213 Mohammed Simo Arredouani, PhD .............................................. 215 William C. DeWolf, MD W. Mike Schopperle, PhD ......................................................... 219 Martin Sanda, MD .................................................................223 Andrew A. Wagner, MD ...........................................................229 iv | Beth Israel Deaconess Medical Center Table of Contents Division of Vascular and Endovascular Surgery ..................... 233 Elliot L. Chaikof, MD, PhD ......................................................235 Christiane Ferran, MD, PhD....................................................... 241 Elzbieta Kaczmarek, PhD ..........................................................251 Frank W. LoGerfo, MD ............................................................255 Marc L. Schermerhorn, MD ...................................................... 271 Department of Surgery Research Annual Report 2011 | v vi | Beth Israel Deaconess Medical Center Overview of Surgical Research–2011 Overview of Introduction Surgical Research In addition to delivering outstanding patient care, research (basic, clinical, and translational) constitutes one of the cornerstones and missions of the Department of Surgery. Research programs in Surgery at Beth Israel Deaconess Medical Center (BIDMC) include Cancer Biology, Inflammation, Development, Vascular Biology, Cardiothoracic research, Transplantation- Immunology, Obesity-Nutrition-Metabolism, Wound Healing, Epithelial and Endothelial Biology, Bioengineering, and Clinical Outcomes. The Office for Surgical Research provides an administrative infrastructure to facilitate research in the Department of Surgery. Surgical Research is headed by Per-Olof Hasselgren, MD, PhD, who is Vice Chairman for Research in Surgery at Beth Israel Deaconess Medical Center (BIDMC) and the George H.A. Clowes Jr. Professor of Surgery at Harvard Medical School. Susan J. Hagen, PhD, who is Associate Vice-Chair for Research in Surgery and Associate Professor of Surgery at Harvard Medical School, assists with the management of Surgical Research. Surgical Research activities are supported by an administrative pool, with Rachel St. Fort as the former Administrative Supervisor and Molly Jay as the Administrative Assistant. Surgical Research has the following responsibilities: 1) Pre-award review and approval of all grant submissions in the Department of Surgery. This includes assisting in the process of submission of grant applications (collaborative or T32 grant applications) and interaction with the BIDMC Office of Sponsored Programs; 2) Management of research space, including laboratory and office space. For this, the allocation of research space within the department is overseen, shared tissue culture facilities are maintained, and the department is represented at various institutional committees and subcommittees dealing with research space at the BIDMC; 3) Organizing research seminars and other departmental research functions; 4) Tracking academic benchmarks
Recommended publications
  • Department of Conferences and Meetings Management
    ORGANIZATION OF AMERICAN STATES Inter-American Council for Integral Development (CIDI) SECOND MEETING OF THE WORKING GROUPS OEA/Ser.L/XIX.VI.2 OF THE XVI INTER-AMERICAN CONFERENCE CIMT-16/GT1-GT2/doc.9/11 OF MINISTERS OF LABOR (IACML) 12 May 2011 May 17-19, 2011 Original: Spanish Washington, D.C. RESULTS WORKSHOP “DECENTRALIZED PUBLIC EMPLOYMENT SERVICES AND THEIR LINKAGE WITH THE BUSINESS WORLD". Americas – Europe Interregional Event • Mexico City, March 16 to 18, 2011 Results Workshop “Decentralized Public Employment Services and their Linkage with the Business World". Americas – Europe Interregional Event • Mexico City, March 16 to 18, 2011 Contents 1. Overview..……………………………………………………………… 2 2. Conclusions …………………………………………………………… 3 3. Ideas arising from the working groups……………................ 9 4. Results of the evaluations....................………………………….. 11 5. Final agenda ……………………………………………………………. 12 6. List of Participants..... ………………………………………………. 15 Results of the Workshop “Decentralised Public Employment Services and their Linkage with the Business World”, Mexico City, March 16 to 18, 2011. Workshop “Decentralised Public Employment Services and their Linkage with the Business World". Americas – Europe Interregional Event 1. Overview Date: March 16 to 18, 2011 Venue: Nuevo León I Room ‐ Fiesta Americana Reforma Hotel, Mexico City Address: Av. Paseo de la Reforma #80, piso 1, Col. Juárez, Del. Cuauhtémoc, C.P. 06600, México, D.F. This workshop was jointly organised by the World Association of Public Employment Services (WAPES), the Ministry of Labor and Social Welfare (STPS) of Mexico, the Ministry of Labor, Employment and Social Security of Argentina and the Organization of American States’ (OAS) Department of Social Development and Employment, which operates the Inter‐American Network for Labor Administration (RIAL).
    [Show full text]
  • Pharmacological Agents Currently in Clinical Trials for Disorders in Neurogastroenterology
    Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri J Clin Invest. 2013;123(10):4111-4120. https://doi.org/10.1172/JCI70837. Clinical Review Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain. Find the latest version: https://jci.me/70837/pdf Review Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota, USA. Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in under- standing the mechanisms of these disorders, through basic and translational research, and in targeting the recep- tors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastropa- resis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • ( 12 ) United States Patent
    US010317418B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 ,317 ,418 B2 Goosens (45 ) Date of Patent: * Jun . 11 , 2019 (54 ) USE OF GHRELIN OR FUNCTIONAL 7 , 479 ,271 B2 1 / 2009 Marquis et al . GHRELIN RECEPTOR AGONISTS TO 7 ,632 , 809 B2 12 / 2009 Chen 7 ,666 , 833 B2 2 /2010 Ghigo et al. PREVENT AND TREAT STRESS -SENSITIVE 7 , 901 ,679 B2 3 / 2011 Marquis et al . PSYCHIATRIC ILLNESS 8 ,013 , 015 B2 9 / 2011 Harran et al . 8 ,293 , 709 B2 10 /2012 Ross et al . (71 ) Applicant: Massachusetts Institute of 9 ,724 , 396 B2 * 8 / 2017 Goosens A61K 38 /27 9 , 821 ,042 B2 * 11 /2017 Goosens .. A61K 39/ 0005 Technology , Cambridge , MA (US ) 10 , 039 ,813 B2 8 / 2018 Goosens 2002/ 0187938 A1 12 / 2002 Deghenghi (72 ) Inventor : Ki Ann Goosens, Cambridge , MA (US ) 2003 / 0032636 Al 2 /2003 Cremers et al. 2004 / 0033948 Al 2 / 2004 Chen ( 73 ) Assignee : Massachusetts Institute of 2005 / 0070712 A1 3 /2005 Kosogof et al. Technology , Cambridge , MA (US ) 2005 / 0148515 Al 7/ 2005 Dong 2005 / 0187237 A1 8 / 2005 Distefano et al. 2005 /0191317 A1 9 / 2005 Bachmann et al. ( * ) Notice : Subject to any disclaimer , the term of this 2005 /0201938 A1 9 /2005 Bryant et al. patent is extended or adjusted under 35 2005 /0257279 AL 11 / 2005 Qian et al. U . S . C . 154 ( b ) by 0 days. 2006 / 0025344 Al 2 /2006 Lange et al. 2006 / 0025566 A 2 /2006 Hoveyda et al. This patent is subject to a terminal dis 2006 / 0293370 AL 12 / 2006 Saunders et al .
    [Show full text]
  • Anorexia Nervosa and Endocrinology: a Clinical Update Støving, René Klinkby
    University of Southern Denmark MECHANISMS IN ENDOCRINOLOGY Anorexia nervosa and endocrinology: a clinical update Støving, René Klinkby Published in: European Journal of Endocrinology DOI: 10.1530/EJE-18-0596 Publication date: 2019 Document version: Final published version Document license: CC BY Citation for pulished version (APA): Støving, R. K. (2019). MECHANISMS IN ENDOCRINOLOGY: Anorexia nervosa and endocrinology: a clinical update. European Journal of Endocrinology, 180(1), R9-R27. https://doi.org/10.1530/EJE-18-0596 Go to publication entry in University of Southern Denmark's Research Portal Terms of use This work is brought to you by the University of Southern Denmark. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply: • You may download this work for personal use only. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying this open access version If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to [email protected] Download date: 28. Sep. 2021 1 180 R K Støving Anorexia nervosa and 180:1 R9–R27 Review endocrinology MECHANISMS IN ENDOCRINOLOGY Anorexia nervosa and endocrinology: a clinical update René Klinkby Støving1,2,3 Correspondence 1Nutrition Clinic, Center for Eating Disorders, Odense University Hospital, 2Endocrine Elite Research Centre, Institute should be addressed of Clinical Research, University of South Denmark, Faculty of Health Sciences, and 3Psychiatric Services in the Region to R K Støving of Southern Denmark, Odense, Denmark Email [email protected] Abstract Anorexia nervosa is a syndrome, that is collections of symptoms, which is not defined by its etiology.
    [Show full text]
  • Supplemental Table
    Supplementary Information DMD-AR-2020-000131 Evaluation of the disconnect between hepatocyte and microsome intrinsic clearance and in vitro in vivo extrapolation performance. Beth Williamson, Stephanie Harlfinger, Dermot F McGinnity Drug Metabolism and Pharmacokinetics, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK. Table S1. Compound physicochemical properties and in vitro ADME data. ACD ACD ACD Human Hep CLint Human Mic CLint Human Main Name MW Ion Class HBD HBA TPSA LogD 6 fuinc pKa A1 pKa B1 LogP (µL/min/x10 ) (µL/min/mg) fup isoform Chlorpromazine 318.9 Base 2 32 9.6 3.4 5.4 20 39 0.060 0.026 CYP2D6 Prochlorperazine 374.0 Base 3 35 7.7 3.6 4.8 12 2 0.023 0.141 CYP2D6 Dipyridamole 504.6 Neutral 4 12 145 6.5 3.8 0.3 28 96 0.407 0.048 UGT Erlotinib 393.4 Neutral 1 7 75 5.5 3.3 3.0 5 20 0.504 0.052 CYP3A Promethazine 284.4 Base 2 32 9.1 2.8 4.6 9 1 0.144 0.090 CYP2D6 Propranolol 259.4 Base 2 3 41 9.5 1.3 3.3 10 29 0.467 0.243 CYP2D6 Rosiglitazone 357.4 Neutral 1 5 97 6.3 6.5 2.5 2.8 13 37 0.514 0.003 Other Ondansetron 293.4 Base 4 40 6.8 1.6 2.8 3 8 0.842 0.435 CYP3A Amsacrine 393.5 Neutral 2 5 89 8.2 3.1 3.2 11 40 0.434 0.007 CYP1A Antazoline 265.4 Base 1 3 28 10.3 1.4 3.6 52 195 0.726 0.562 CYP3A Gefitinib 446.9 Base 1 7 69 7.0 3.7 3.7 4 44 0.214 0.035 CYP3A Edaravone 174.2 Neutral 1 3 33 2.7 0.5 1.1 2 65 0.828 0.001 UGT Semaxanib 238.3 Neutral 2 2 45 13.2 1.5 3.4 3.0 28 68 0.036 0.031 CYP3A Verapamil 454.6 Base 6 64 8.1 2.6 4.0 23 180 0.548 0.155 CYP3A Imatinib 493.6 Base 2 7 86 13.3 7.6 2.5 3.1 3 35 0.405
    [Show full text]
  • 148 LATIN AMERICAN THEATRE REVIEW Egon Wolff in US
    148 LATIN AMERICAN THEATRE REVIEW Egon Wolff in U.S. At the MLA convention in San Francisco in December, 1987, Egon Wolff will participate in a special seminar on his theatre within the context of the Chilean theatre of his generation. In addition, Mr. Wolff may be available to visit colleges and universities in the United States early in 1988. If you are interested in inviting him to your campus, please contact Prof. Leon F. Lyday, Department of Spanish, Italian and Portuguese, The Pennsylvania State University, University Park, PA 16802. Triana and Gámbaro in U.S. Dartmouth College will host a two-day symposium on the theatre of José Triana and Griselda Gámbaro on October 7-8, 1987. Both playwrights are expected to be in attendance for the occasion to interact with participants who will give presentations on their theatre. For further information, please contact Prof. Diana Taylor, Department of Spanish and Portuguese, Dartmouth College, Hanover, NH 03755. Primer Encuentro Internacional de Teatro Antropológico Coordinado por el Maestro Eugenio Barba, director del Nordisk Tea- terlaboratorium Project y de la ISTA (International School of Theatre Anthropology), este encuentro se celebró en Bahía Blanca, Argentina, entre el 6 y 12 de abril de 1987. Participaron los grupos Odin Teatret de Dinamarca, Tadcabile di Bergamo, Potlach de Fara Sabina (Italia) y grupos lati­ noamericanos de Chile, México, Cuba, Brasil y Uruguay. Con el objetivo del encuentro de evitar "la maratón del festival,'' se puso el acento en el encuentro del trabajo y no en la presentación de espectáculos. Por la mañana, había reuniones de reflexión y discusión de todos los participantes.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • Molecular Medicine Tri-Conference
    Register by January 15 and SAVE up to $200 Premier Sponsors Corporate Sponsors Conference: February 3-5 | Exhibits: February 3-4 Moscone North Convention Center | San Francisco, CA PLENARY KEYNOTES When Drug Research is Personal John F. Crowley, Founder, Novazyme Pharmaceuti cals, Inc. Technology, Aging, and the Brain Biotechnologies GmbH ® Gary W. Small, M.D., Professor, Meso Scale Discovery David Geff en School of Medicine, University of California, Los Angeles Chips, Clones and Living Beyond 100 Paul J.H. Schoemaker, Ph.D., Lead Sponsoring Publicati ons M.B.A., Professor, Wharton School of Business Corporate Support Sponsors Co - Sponsors The State of California Cambridge Healthtech Institute • 250 First Avenue, Suite 300, Needham, MA 02494 Telephone: 781-972-5400 or Toll-Free in the U.S. 888-999-6288 • Fax: 781-972-5425 Tri-Conference.com Media Partners CONFERENCE-AT-A-GLANCE Tuesday, February 2 The Open Access Publisher 8:00 AM Morning Short Course Registration and Coffee 9:00 - 12:00 PM Morning Short Courses (Courses 1-6) 10:15 - 10:30 Networking Coffee Break 1:00 - 2:00 Afternoon Short Course Registration 2:00 - 5:00 Afternoon Short Courses (Courses 7-12) 3:15 - 3:30 Networking Refreshment Break 5:00 Close of Day Wednesday, February 3 7:00 AM Registration and Morning Coffee 8:00 - 9:40 Plenary Keynotes 9:40 - 11:00 Grand Opening Refreshment Break in the Exhibit Hall Nanomedicine 11:00 - 12:40 PM Concurrent Channels 12:40 - 1:45 Sponsored Luncheon Presentations or Lunch on Your Own 1:45 - 2:15 Dessert in the Exhibit Hall 2:15 - 4:20
    [Show full text]
  • Howickkp Phd2018.Pdf
    UCC Library and UCC researchers have made this item openly available. Please let us know how this has helped you. Thanks! Title Ghrelin system signalling in appetite and reward: in vitro and in vivo perspectives Author(s) Howick, Kenneth P. Publication date 2018 Original citation Howick, K. P. 2018. Ghrelin system signalling in appetite and reward: in vitro and in vivo perspectives. PhD Thesis, University College Cork. Type of publication Doctoral thesis Rights © 2018, Kenneth P. Howick. http://creativecommons.org/licenses/by-nc-nd/3.0/ Item downloaded http://hdl.handle.net/10468/8017 from Downloaded on 2021-10-07T02:39:18Z Ollscoil na hÉireann, Corcaigh National University of Ireland, Cork School of Pharmacy/ Department of Anatomy & Neuroscience Ghrelin system signalling in appetite and reward: in vitro and in vivo perspectives Thesis presented by Kenneth Patrick Howick, BPharm, MPharm under the supervision of Dr. Brendan Griffin Dr. Harriët Schellekens for the degree of Doctor of Philosophy December 2018 Table of Contents Table of Contents ..................................................................................................... I List of Appendices ................................................................................................ XI Glossary of Terms ................................................................................................. XI Declaration .......................................................................................................... XIII Author Contributions..........................................................................................
    [Show full text]
  • Download Program
    THE FLEA THEATER NIEGEL SMITH, ARTISTIC DIRECTOR CAROL OSTROW, PRODUCING DIRECTOR PRESENTS Southern Promises BY THOMAS BRADSHAW DIRECTED BY NIEGEL SMITH FEATURING THE BATS ADAM COY, DARBY DAVIS, MARCUS JONES, TIMOTHY PARK, YVONNE JESSICA PRUITT, JAHSIAH RIVERA, ANA SEMEDO, LAMBERT TAMIN, SHAKUR TOLLIVER, ADRAIN WASHINGTON, SELAMAWIT WORKU, BRITTANY ZAKEN JASON SHERWOOD SCENIC DESIGNER CLAUDIA BROWN COSTUME DESIGNER JORGE ARROYO LIGHTING DESIGNER FABIAN OBISPO SOUND DESIGNER NIKIYA MATHIS HAIR/MAKEUP DESIGNER ROCIO MENDEZ VIOLENCE/INTIMACY CHOREOGRAPHER ANNA KOVACS STAGE MANAGER TYLER THOMAS AssISTANT DIRECTOR CAST (In Order of Apperance) Isaiah..............................................................................Darby Davis Elizabeth.....................................................................Brittany Zaken Benjamin.....................................................................Shakur Tolliver Charlotte............................................................Yvonne Jessica Pruitt David...........................................................................Jahsiah Rivera John...............................................................................Marcus Jones Doctor.............................................................................Timothy Park Imaginary Slave / Emmanuel / David (U/S)/Benjamin (U/S)......Adrain Washington Sarah/Charlotte(U/S)...............................................Selamawit Worku Atticus................................................................................Adam
    [Show full text]